PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials

医学 卡铂 培美曲塞 贝伐单抗 内科学 肺癌 化疗 肿瘤科 胃肠病学 顺铂 外科
作者
Xiangjiao Meng,Yu Chen,Ligang Xing,Xinchao Liu,Kaikai Zhao,Liyang Jiang,Li Zhang,Caicun Zhou,Jinming Yu
出处
期刊:BMJ Open Respiratory Research [BMJ]
卷期号:9 (1): e001294-e001294 被引量:1
标识
DOI:10.1136/bmjresp-2022-001294
摘要

Background To date, none of randomised trials aim to compare the efficacy of programmed death 1 (PD-1) inhibitor plus chemotherapy and bevacizumab plus chemotherapy as first-line treatment for non-squamous non-small-cell lung cancer (NSCLC). This analysis pooled prospective data to compare the survival benefits of the two regimens for advanced NSCLC without targetable genetic mutations. Methods Data were pooled from three randomised phase III clinical trials: NCT03607539 , NCT03134872 and NCT02954172 . 466 patients received PD-1 inhibitor (200 mg) plus pemetrexed (500 mg/m²) and platinum (cisplatin 75 mg/m 2 or carboplatin area under the curve (AUC) 5 mg/mL/min), while 432 patients received bevacizumab (15 mg/kg) plus paclitaxel (175 mg/m 2 ) and carboplatin (AUC 6 mg/mL/min). Propensity score matching in a 1:1 ratio was performed to balance baseline characteristics of the two arms. The endpoints of this analysis were progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). Results In total, 375 patients in each arm were matched. With a median follow-up of 23 months (IQR 21–26), results showed that median PFS was significantly prolonged in the PD-1 inhibitor arm than in the bevacizumab arm (10.1 vs 7.4 months; HR 0.62, 95% CI 0.52 to 0.73, p<0.001). Improved OS was also demonstrated in the PD-1 inhibitor arm (27.9 vs 20.2 months; HR 0.75 95% CI 0.61 to 0.91, p=0.004). ORR in the PD-1 inhibitor arm was 56.8%, while that in the bevacizumab arm was 45.1%. However, exploratory subgroup analysis indicated that median PFS and median OS of the two arms were comparable in patients with negative programmed death ligand 1 expression or in patients aged ≥65 years old. Conclusions PD-1 inhibitor plus chemotherapy was associated with significant survival benefits compared with bevacizumab plus chemotherapy in patients with advanced non-squamous NSCLC, which provides evidence support to guide clinical practice. Nonetheless, the comparative survival outcomes in several subgroups indicated that bevacizumab plus chemotherapy still mattered.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zyyyy完成签到,获得积分10
刚刚
温润如玉坤完成签到,获得积分10
1秒前
十一完成签到,获得积分20
1秒前
cm完成签到,获得积分10
2秒前
一台小钢炮完成签到,获得积分10
3秒前
3秒前
Wguan发布了新的文献求助20
3秒前
英俊的铭应助asdf采纳,获得10
3秒前
我是老大应助123采纳,获得10
4秒前
陨落的繁星完成签到,获得积分10
4秒前
十一发布了新的文献求助10
4秒前
顺科研发布了新的文献求助10
4秒前
李多多完成签到,获得积分10
4秒前
浪浪山第一酷完成签到,获得积分10
5秒前
眼睛大的胡萝卜完成签到 ,获得积分10
5秒前
顺心的飞飞完成签到,获得积分10
5秒前
ymh完成签到,获得积分10
6秒前
dropofwater完成签到,获得积分10
6秒前
文章快快来完成签到,获得积分10
6秒前
ZX612完成签到,获得积分10
6秒前
全糖完成签到,获得积分10
6秒前
DICPGLF完成签到,获得积分10
6秒前
炎帝完成签到 ,获得积分10
7秒前
Dritsw应助熬夜的桃子采纳,获得10
8秒前
李爱国应助renwoxing采纳,获得10
8秒前
QQ完成签到,获得积分10
8秒前
9秒前
9秒前
9秒前
传奇3应助大美女采纳,获得10
9秒前
哈哈2022完成签到,获得积分10
9秒前
7890733完成签到,获得积分10
10秒前
11秒前
man完成签到 ,获得积分10
11秒前
张兰发布了新的文献求助10
11秒前
11秒前
FashionBoy应助hhh采纳,获得10
12秒前
冷酷的松思完成签到,获得积分10
12秒前
修梨完成签到,获得积分20
12秒前
0713完成签到,获得积分10
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968608
求助须知:如何正确求助?哪些是违规求助? 3513486
关于积分的说明 11168243
捐赠科研通 3248926
什么是DOI,文献DOI怎么找? 1794540
邀请新用户注册赠送积分活动 875188
科研通“疑难数据库(出版商)”最低求助积分说明 804676